Ma Songjiang 4
4 · GYRE THERAPEUTICS, INC. · Filed Mar 13, 2025
Insider Transaction Report
Form 4
Ma Songjiang
DirectorPresident
Transactions
- Sale
Common Stock
2025-03-11$11.40/sh−2,000$22,800→ 2,837,260 total(indirect: By Spouse) - Sale
Common Stock
2025-03-12$11.74/sh−2,000$23,480→ 2,835,260 total(indirect: By Spouse)
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.92 to $11.845. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.40 to $12.135. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.